The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research
Posted on: Wednesday, 27 August 2008, 18:00 CDT
CHICAGO, Aug. 27 /PRNewswire/ -- The British Midlands Development Corporation today announced that scientists at The University of Nottingham have made a crucial breakthrough in the battle to slow or prevent the onset of a very common type of dementia and Parkinson's disease.
The researchers have genetically produced the first ever mouse model with the type of brain degeneration, or nerve cell loss, seen in Lewy body disease and Parkinson's disease, which could lead to more targeted drugs to treat the degenerative conditions.
The study has been carried out by Professor John Mayer and Dr Lynn Bedford in the University's School of Biomedical Sciences, in collaboration with Professor Jim Lowe in the School of Molecular Medical Sciences.
Professor John Mayer said: "Current drugs given to people with Lewy body and Parkinson's disease simply treat the symptoms. This model is the first platform to understand how the brain cell deterioration takes place. We will use this model to identify targets for new drugs to slow or prevent the disease."
Lewy body disease, also known as dementia with Lewy bodies (DLB) shares characteristics with both Alzheimer's and Parkinson's diseases. The number of people with dementia is forecast to double within a generation.
Dr Kieran Breen, Director of Research and Development at the Parkinson's Disease Society, added: "The formation of Lewy bodies is a key event in the development of nerve cell death associated with Parkinson's disease. Understanding how these are formed will help us to figure out what happens when nerve cells die in Parkinson's and from this to develop therapies that will ultimately provide a cure for the condition."
"Universities in the Midlands continue to set the bar in innovation and discovery," said Vern Sebby, President and CEO of British Midlands Development Corporation, "The British Midlands is one of Europe's premier locations for the advancement of medicine and life sciences. All of the region's 18 universities have unique areas of scientific expertise, which fuel the region's record of innovation in the field."
About British Midlands Development Corporation
The British Midlands Development Corporation is the North American economic development agency for central England. The Midlands region is located just one hour to the north of London and includes the major commercial centers of Birmingham, Nottingham, Coventry and Northampton.
As an agency funded by the UK Government, The British Midlands Development Corporation provides specialist advice and support to North American companies seeking to establish a presence or expand a current operation in the region.
The British Midlands Development Corporation is based in Chicago with branch offices in Boston, Washington, DC and San Jose.
For more information, please visit our website at http://www.thebritishmidlands.com/.
Press Contact Laura Nicholas laura@thepontgroup.com 646 290 5989
British Midlands Development Corporation
CONTACT: Laura Nicholas of The Pont Group, +1-646-290-5989,laura@thepontgroup.com, for British Midlands Development Corporation
Web site: http://www.thebritishmidlands.com/
Source: PRNewswire
Related Articles
- The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments
- Research Shows Fish Oil Protects Against Diseases Like Parkinson's
- Link Medicine Completes $40 Million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders
- Positron Corporation and Disease Management, LLC Sign Agreement to Co-Develop a Coronary Artery Disease Reversal and Prevention Software Program and Total Disease Management Solution
- Highly Promising Dutch Research Into Alzheimer's Disease and Parkinson's Disease
- Research and Development on Crohn's Disease & Ulcerative Colitis
- Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration Enters Development for Respiratory Disease
- Pharmaceutical and Biotechnology Companies Are Increasingly Shifting Their Drug Development for Infectious Diseases From Antibacterial to Antiviral Discovery and Development
- PET Scans Predict Development of Lung Disease Following Trauma
 |
 |
User Comments (0)
RSS Feeds